Global Neoantigen Vaccine Supply, Demand and Key Producers, 2024-2030

Description

The global Neoantigen Vaccine market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report studies the global Neoantigen Vaccine demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Neoantigen Vaccine, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Neoantigen Vaccine that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Neoantigen Vaccine total market, 2019-2030, (USD Million)
Global Neoantigen Vaccine total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Neoantigen Vaccine total market, key domestic companies and share, (USD Million)
Global Neoantigen Vaccine revenue by player and market share 2019-2024, (USD Million)
Global Neoantigen Vaccine total market by Type, CAGR, 2019-2030, (USD Million)
Global Neoantigen Vaccine total market by Application, CAGR, 2019-2030, (USD Million).

This reports profiles major players in the global Neoantigen Vaccine market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Merck & Co Inc, Eli Lilly and Company, BioNTech, Roche Holding AG, OSE Immunotherapeutics, Gritstone Bio, Moderna and Avidea Technologies, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Neoantigen Vaccine market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Neoantigen Vaccine Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Neoantigen Vaccine Market, Segmentation by Type
    Personalized Vaccine
    Off-the shelf Vaccine

Global Neoantigen Vaccine Market, Segmentation by Application
    Lung Cancer
    Melanoma Cancer
    Gastrointestinal Cancer
    Brain Cancer
    Others

Companies Profiled:
    Pfizer
    Merck & Co Inc
    Eli Lilly and Company
    BioNTech
    Roche Holding AG
    OSE Immunotherapeutics
    Gritstone Bio
    Moderna
    Avidea Technologies
    Vaccibody AS
    Agenus Inc
    Novogene
    ZIOPHARM Oncology
    ISA Pharmaceuticals
    BrightPath Biotherapeutics
    Vaximm AG
    Medigene AG
    Genocea Biosciences Inc
    Advaxis
    Nouscom

Key Questions Answered
1. How big is the global Neoantigen Vaccine market?
2. What is the demand of the global Neoantigen Vaccine market?
3. What is the year over year growth of the global Neoantigen Vaccine market?
4. What is the total value of the global Neoantigen Vaccine market?
5. Who are the major players in the global Neoantigen Vaccine market?

Table of Contents

1 Supply Summary
    1.1 Neoantigen Vaccine Introduction
    1.2 World Neoantigen Vaccine Market Size & Forecast (2019 & 2023 & 2030)
    1.3 World Neoantigen Vaccine Total Market by Region (by Headquarter Location)
        1.3.1 World Neoantigen Vaccine Market Size by Region (2019-2030), (by Headquarter Location)
        1.3.2 United States Neoantigen Vaccine Market Size (2019-2030)
        1.3.3 China Neoantigen Vaccine Market Size (2019-2030)
        1.3.4 Europe Neoantigen Vaccine Market Size (2019-2030)
        1.3.5 Japan Neoantigen Vaccine Market Size (2019-2030)
        1.3.6 South Korea Neoantigen Vaccine Market Size (2019-2030)
        1.3.7 ASEAN Neoantigen Vaccine Market Size (2019-2030)
        1.3.8 India Neoantigen Vaccine Market Size (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Neoantigen Vaccine Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Neoantigen Vaccine Major Market Trends

2 Demand Summary
    2.1 World Neoantigen Vaccine Consumption Value (2019-2030)
    2.2 World Neoantigen Vaccine Consumption Value by Region
        2.2.1 World Neoantigen Vaccine Consumption Value by Region (2019-2024)
        2.2.2 World Neoantigen Vaccine Consumption Value Forecast by Region (2025-2030)
    2.3 United States Neoantigen Vaccine Consumption Value (2019-2030)
    2.4 China Neoantigen Vaccine Consumption Value (2019-2030)
    2.5 Europe Neoantigen Vaccine Consumption Value (2019-2030)
    2.6 Japan Neoantigen Vaccine Consumption Value (2019-2030)
    2.7 South Korea Neoantigen Vaccine Consumption Value (2019-2030)
    2.8 ASEAN Neoantigen Vaccine Consumption Value (2019-2030)
    2.9 India Neoantigen Vaccine Consumption Value (2019-2030)

3 World Neoantigen Vaccine Companies Competitive Analysis
    3.1 World Neoantigen Vaccine Revenue by Player (2019-2024)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Neoantigen Vaccine Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Neoantigen Vaccine in 2023
        3.2.3 Global Concentration Ratios (CR8) for Neoantigen Vaccine in 2023
    3.3 Neoantigen Vaccine Company Evaluation Quadrant
    3.4 Neoantigen Vaccine Market: Overall Company Footprint Analysis
        3.4.1 Neoantigen Vaccine Market: Region Footprint
        3.4.2 Neoantigen Vaccine Market: Company Product Type Footprint
        3.4.3 Neoantigen Vaccine Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Neoantigen Vaccine Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Neoantigen Vaccine Market Size Comparison (2019 & 2023 & 2030) (by Headquarter Location)
        4.1.2 United States VS China: Neoantigen Vaccine Revenue Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States Based Companies VS China Based Companies: Neoantigen Vaccine Consumption Value Comparison
        4.2.1 United States VS China: Neoantigen Vaccine Consumption Value Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Neoantigen Vaccine Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States Based Neoantigen Vaccine Companies and Market Share, 2019-2024
        4.3.1 United States Based Neoantigen Vaccine Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Neoantigen Vaccine Revenue, (2019-2024)
    4.4 China Based Companies Neoantigen Vaccine Revenue and Market Share, 2019-2024
        4.4.1 China Based Neoantigen Vaccine Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Neoantigen Vaccine Revenue, (2019-2024)
    4.5 Rest of World Based Neoantigen Vaccine Companies and Market Share, 2019-2024
        4.5.1 Rest of World Based Neoantigen Vaccine Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Neoantigen Vaccine Revenue, (2019-2024)

5 Market Analysis by Type
    5.1 World Neoantigen Vaccine Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Personalized Vaccine
        5.2.2 Off-the shelf Vaccine
    5.3 Market Segment by Type
        5.3.1 World Neoantigen Vaccine Market Size by Type (2019-2024)
        5.3.2 World Neoantigen Vaccine Market Size by Type (2025-2030)
        5.3.3 World Neoantigen Vaccine Market Size Market Share by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Neoantigen Vaccine Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Lung Cancer
        6.2.2 Melanoma Cancer
        6.2.3 Gastrointestinal Cancer
        6.2.4 Brain Cancer
        6.2.5 Brain Cancer
    6.3 Market Segment by Application
        6.3.1 World Neoantigen Vaccine Market Size by Application (2019-2024)
        6.3.2 World Neoantigen Vaccine Market Size by Application (2025-2030)
        6.3.3 World Neoantigen Vaccine Market Size by Application (2019-2030)

7 Company Profiles
    7.1 Pfizer
        7.1.1 Pfizer Details
        7.1.2 Pfizer Major Business
        7.1.3 Pfizer Neoantigen Vaccine Product and Services
        7.1.4 Pfizer Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.1.5 Pfizer Recent Developments/Updates
        7.1.6 Pfizer Competitive Strengths & Weaknesses
    7.2 Merck & Co Inc
        7.2.1 Merck & Co Inc Details
        7.2.2 Merck & Co Inc Major Business
        7.2.3 Merck & Co Inc Neoantigen Vaccine Product and Services
        7.2.4 Merck & Co Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.2.5 Merck & Co Inc Recent Developments/Updates
        7.2.6 Merck & Co Inc Competitive Strengths & Weaknesses
    7.3 Eli Lilly and Company
        7.3.1 Eli Lilly and Company Details
        7.3.2 Eli Lilly and Company Major Business
        7.3.3 Eli Lilly and Company Neoantigen Vaccine Product and Services
        7.3.4 Eli Lilly and Company Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.3.5 Eli Lilly and Company Recent Developments/Updates
        7.3.6 Eli Lilly and Company Competitive Strengths & Weaknesses
    7.4 BioNTech
        7.4.1 BioNTech Details
        7.4.2 BioNTech Major Business
        7.4.3 BioNTech Neoantigen Vaccine Product and Services
        7.4.4 BioNTech Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.4.5 BioNTech Recent Developments/Updates
        7.4.6 BioNTech Competitive Strengths & Weaknesses
    7.5 Roche Holding AG
        7.5.1 Roche Holding AG Details
        7.5.2 Roche Holding AG Major Business
        7.5.3 Roche Holding AG Neoantigen Vaccine Product and Services
        7.5.4 Roche Holding AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.5.5 Roche Holding AG Recent Developments/Updates
        7.5.6 Roche Holding AG Competitive Strengths & Weaknesses
    7.6 OSE Immunotherapeutics
        7.6.1 OSE Immunotherapeutics Details
        7.6.2 OSE Immunotherapeutics Major Business
        7.6.3 OSE Immunotherapeutics Neoantigen Vaccine Product and Services
        7.6.4 OSE Immunotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.6.5 OSE Immunotherapeutics Recent Developments/Updates
        7.6.6 OSE Immunotherapeutics Competitive Strengths & Weaknesses
    7.7 Gritstone Bio
        7.7.1 Gritstone Bio Details
        7.7.2 Gritstone Bio Major Business
        7.7.3 Gritstone Bio Neoantigen Vaccine Product and Services
        7.7.4 Gritstone Bio Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.7.5 Gritstone Bio Recent Developments/Updates
        7.7.6 Gritstone Bio Competitive Strengths & Weaknesses
    7.8 Moderna
        7.8.1 Moderna Details
        7.8.2 Moderna Major Business
        7.8.3 Moderna Neoantigen Vaccine Product and Services
        7.8.4 Moderna Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.8.5 Moderna Recent Developments/Updates
        7.8.6 Moderna Competitive Strengths & Weaknesses
    7.9 Avidea Technologies
        7.9.1 Avidea Technologies Details
        7.9.2 Avidea Technologies Major Business
        7.9.3 Avidea Technologies Neoantigen Vaccine Product and Services
        7.9.4 Avidea Technologies Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.9.5 Avidea Technologies Recent Developments/Updates
        7.9.6 Avidea Technologies Competitive Strengths & Weaknesses
    7.10 Vaccibody AS
        7.10.1 Vaccibody AS Details
        7.10.2 Vaccibody AS Major Business
        7.10.3 Vaccibody AS Neoantigen Vaccine Product and Services
        7.10.4 Vaccibody AS Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.10.5 Vaccibody AS Recent Developments/Updates
        7.10.6 Vaccibody AS Competitive Strengths & Weaknesses
    7.11 Agenus Inc
        7.11.1 Agenus Inc Details
        7.11.2 Agenus Inc Major Business
        7.11.3 Agenus Inc Neoantigen Vaccine Product and Services
        7.11.4 Agenus Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.11.5 Agenus Inc Recent Developments/Updates
        7.11.6 Agenus Inc Competitive Strengths & Weaknesses
    7.12 Novogene
        7.12.1 Novogene Details
        7.12.2 Novogene Major Business
        7.12.3 Novogene Neoantigen Vaccine Product and Services
        7.12.4 Novogene Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.12.5 Novogene Recent Developments/Updates
        7.12.6 Novogene Competitive Strengths & Weaknesses
    7.13 ZIOPHARM Oncology
        7.13.1 ZIOPHARM Oncology Details
        7.13.2 ZIOPHARM Oncology Major Business
        7.13.3 ZIOPHARM Oncology Neoantigen Vaccine Product and Services
        7.13.4 ZIOPHARM Oncology Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.13.5 ZIOPHARM Oncology Recent Developments/Updates
        7.13.6 ZIOPHARM Oncology Competitive Strengths & Weaknesses
    7.14 ISA Pharmaceuticals
        7.14.1 ISA Pharmaceuticals Details
        7.14.2 ISA Pharmaceuticals Major Business
        7.14.3 ISA Pharmaceuticals Neoantigen Vaccine Product and Services
        7.14.4 ISA Pharmaceuticals Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.14.5 ISA Pharmaceuticals Recent Developments/Updates
        7.14.6 ISA Pharmaceuticals Competitive Strengths & Weaknesses
    7.15 BrightPath Biotherapeutics
        7.15.1 BrightPath Biotherapeutics Details
        7.15.2 BrightPath Biotherapeutics Major Business
        7.15.3 BrightPath Biotherapeutics Neoantigen Vaccine Product and Services
        7.15.4 BrightPath Biotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.15.5 BrightPath Biotherapeutics Recent Developments/Updates
        7.15.6 BrightPath Biotherapeutics Competitive Strengths & Weaknesses
    7.16 Vaximm AG
        7.16.1 Vaximm AG Details
        7.16.2 Vaximm AG Major Business
        7.16.3 Vaximm AG Neoantigen Vaccine Product and Services
        7.16.4 Vaximm AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.16.5 Vaximm AG Recent Developments/Updates
        7.16.6 Vaximm AG Competitive Strengths & Weaknesses
    7.17 Medigene AG
        7.17.1 Medigene AG Details
        7.17.2 Medigene AG Major Business
        7.17.3 Medigene AG Neoantigen Vaccine Product and Services
        7.17.4 Medigene AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.17.5 Medigene AG Recent Developments/Updates
        7.17.6 Medigene AG Competitive Strengths & Weaknesses
    7.18 Genocea Biosciences Inc
        7.18.1 Genocea Biosciences Inc Details
        7.18.2 Genocea Biosciences Inc Major Business
        7.18.3 Genocea Biosciences Inc Neoantigen Vaccine Product and Services
        7.18.4 Genocea Biosciences Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.18.5 Genocea Biosciences Inc Recent Developments/Updates
        7.18.6 Genocea Biosciences Inc Competitive Strengths & Weaknesses
    7.19 Advaxis
        7.19.1 Advaxis Details
        7.19.2 Advaxis Major Business
        7.19.3 Advaxis Neoantigen Vaccine Product and Services
        7.19.4 Advaxis Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.19.5 Advaxis Recent Developments/Updates
        7.19.6 Advaxis Competitive Strengths & Weaknesses
    7.20 Nouscom
        7.20.1 Nouscom Details
        7.20.2 Nouscom Major Business
        7.20.3 Nouscom Neoantigen Vaccine Product and Services
        7.20.4 Nouscom Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        7.20.5 Nouscom Recent Developments/Updates
        7.20.6 Nouscom Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Neoantigen Vaccine Industry Chain
    8.2 Neoantigen Vaccine Upstream Analysis
    8.3 Neoantigen Vaccine Midstream Analysis
    8.4 Neoantigen Vaccine Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Neoantigen Vaccine Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
    Table 2. World Neoantigen Vaccine Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
    Table 3. World Neoantigen Vaccine Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
    Table 4. World Neoantigen Vaccine Revenue Market Share by Region (2019-2024), (by Headquarter Location)
    Table 5. World Neoantigen Vaccine Revenue Market Share by Region (2025-2030), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Neoantigen Vaccine Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
    Table 8. World Neoantigen Vaccine Consumption Value by Region (2019-2024) & (USD Million)
    Table 9. World Neoantigen Vaccine Consumption Value Forecast by Region (2025-2030) & (USD Million)
    Table 10. World Neoantigen Vaccine Revenue by Player (2019-2024) & (USD Million)
    Table 11. Revenue Market Share of Key Neoantigen Vaccine Players in 2023
    Table 12. World Neoantigen Vaccine Industry Rank of Major Player, Based on Revenue in 2023
    Table 13. Global Neoantigen Vaccine Company Evaluation Quadrant
    Table 14. Head Office of Key Neoantigen Vaccine Player
    Table 15. Neoantigen Vaccine Market: Company Product Type Footprint
    Table 16. Neoantigen Vaccine Market: Company Product Application Footprint
    Table 17. Neoantigen Vaccine Mergers & Acquisitions Activity
    Table 18. United States VS China Neoantigen Vaccine Market Size Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 19. United States VS China Neoantigen Vaccine Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 20. United States Based Neoantigen Vaccine Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Neoantigen Vaccine Revenue, (2019-2024) & (USD Million)
    Table 22. United States Based Companies Neoantigen Vaccine Revenue Market Share (2019-2024)
    Table 23. China Based Neoantigen Vaccine Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Neoantigen Vaccine Revenue, (2019-2024) & (USD Million)
    Table 25. China Based Companies Neoantigen Vaccine Revenue Market Share (2019-2024)
    Table 26. Rest of World Based Neoantigen Vaccine Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Neoantigen Vaccine Revenue, (2019-2024) & (USD Million)
    Table 28. Rest of World Based Companies Neoantigen Vaccine Revenue Market Share (2019-2024)
    Table 29. World Neoantigen Vaccine Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Table 30. World Neoantigen Vaccine Market Size by Type (2019-2024) & (USD Million)
    Table 31. World Neoantigen Vaccine Market Size by Type (2025-2030) & (USD Million)
    Table 32. World Neoantigen Vaccine Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Table 33. World Neoantigen Vaccine Market Size by Application (2019-2024) & (USD Million)
    Table 34. World Neoantigen Vaccine Market Size by Application (2025-2030) & (USD Million)
    Table 35. Pfizer Basic Information, Area Served and Competitors
    Table 36. Pfizer Major Business
    Table 37. Pfizer Neoantigen Vaccine Product and Services
    Table 38. Pfizer Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 39. Pfizer Recent Developments/Updates
    Table 40. Pfizer Competitive Strengths & Weaknesses
    Table 41. Merck & Co Inc Basic Information, Area Served and Competitors
    Table 42. Merck & Co Inc Major Business
    Table 43. Merck & Co Inc Neoantigen Vaccine Product and Services
    Table 44. Merck & Co Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 45. Merck & Co Inc Recent Developments/Updates
    Table 46. Merck & Co Inc Competitive Strengths & Weaknesses
    Table 47. Eli Lilly and Company Basic Information, Area Served and Competitors
    Table 48. Eli Lilly and Company Major Business
    Table 49. Eli Lilly and Company Neoantigen Vaccine Product and Services
    Table 50. Eli Lilly and Company Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 51. Eli Lilly and Company Recent Developments/Updates
    Table 52. Eli Lilly and Company Competitive Strengths & Weaknesses
    Table 53. BioNTech Basic Information, Area Served and Competitors
    Table 54. BioNTech Major Business
    Table 55. BioNTech Neoantigen Vaccine Product and Services
    Table 56. BioNTech Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 57. BioNTech Recent Developments/Updates
    Table 58. BioNTech Competitive Strengths & Weaknesses
    Table 59. Roche Holding AG Basic Information, Area Served and Competitors
    Table 60. Roche Holding AG Major Business
    Table 61. Roche Holding AG Neoantigen Vaccine Product and Services
    Table 62. Roche Holding AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 63. Roche Holding AG Recent Developments/Updates
    Table 64. Roche Holding AG Competitive Strengths & Weaknesses
    Table 65. OSE Immunotherapeutics Basic Information, Area Served and Competitors
    Table 66. OSE Immunotherapeutics Major Business
    Table 67. OSE Immunotherapeutics Neoantigen Vaccine Product and Services
    Table 68. OSE Immunotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 69. OSE Immunotherapeutics Recent Developments/Updates
    Table 70. OSE Immunotherapeutics Competitive Strengths & Weaknesses
    Table 71. Gritstone Bio Basic Information, Area Served and Competitors
    Table 72. Gritstone Bio Major Business
    Table 73. Gritstone Bio Neoantigen Vaccine Product and Services
    Table 74. Gritstone Bio Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 75. Gritstone Bio Recent Developments/Updates
    Table 76. Gritstone Bio Competitive Strengths & Weaknesses
    Table 77. Moderna Basic Information, Area Served and Competitors
    Table 78. Moderna Major Business
    Table 79. Moderna Neoantigen Vaccine Product and Services
    Table 80. Moderna Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 81. Moderna Recent Developments/Updates
    Table 82. Moderna Competitive Strengths & Weaknesses
    Table 83. Avidea Technologies Basic Information, Area Served and Competitors
    Table 84. Avidea Technologies Major Business
    Table 85. Avidea Technologies Neoantigen Vaccine Product and Services
    Table 86. Avidea Technologies Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 87. Avidea Technologies Recent Developments/Updates
    Table 88. Avidea Technologies Competitive Strengths & Weaknesses
    Table 89. Vaccibody AS Basic Information, Area Served and Competitors
    Table 90. Vaccibody AS Major Business
    Table 91. Vaccibody AS Neoantigen Vaccine Product and Services
    Table 92. Vaccibody AS Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 93. Vaccibody AS Recent Developments/Updates
    Table 94. Vaccibody AS Competitive Strengths & Weaknesses
    Table 95. Agenus Inc Basic Information, Area Served and Competitors
    Table 96. Agenus Inc Major Business
    Table 97. Agenus Inc Neoantigen Vaccine Product and Services
    Table 98. Agenus Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 99. Agenus Inc Recent Developments/Updates
    Table 100. Agenus Inc Competitive Strengths & Weaknesses
    Table 101. Novogene Basic Information, Area Served and Competitors
    Table 102. Novogene Major Business
    Table 103. Novogene Neoantigen Vaccine Product and Services
    Table 104. Novogene Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 105. Novogene Recent Developments/Updates
    Table 106. Novogene Competitive Strengths & Weaknesses
    Table 107. ZIOPHARM Oncology Basic Information, Area Served and Competitors
    Table 108. ZIOPHARM Oncology Major Business
    Table 109. ZIOPHARM Oncology Neoantigen Vaccine Product and Services
    Table 110. ZIOPHARM Oncology Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 111. ZIOPHARM Oncology Recent Developments/Updates
    Table 112. ZIOPHARM Oncology Competitive Strengths & Weaknesses
    Table 113. ISA Pharmaceuticals Basic Information, Area Served and Competitors
    Table 114. ISA Pharmaceuticals Major Business
    Table 115. ISA Pharmaceuticals Neoantigen Vaccine Product and Services
    Table 116. ISA Pharmaceuticals Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 117. ISA Pharmaceuticals Recent Developments/Updates
    Table 118. ISA Pharmaceuticals Competitive Strengths & Weaknesses
    Table 119. BrightPath Biotherapeutics Basic Information, Area Served and Competitors
    Table 120. BrightPath Biotherapeutics Major Business
    Table 121. BrightPath Biotherapeutics Neoantigen Vaccine Product and Services
    Table 122. BrightPath Biotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 123. BrightPath Biotherapeutics Recent Developments/Updates
    Table 124. BrightPath Biotherapeutics Competitive Strengths & Weaknesses
    Table 125. Vaximm AG Basic Information, Area Served and Competitors
    Table 126. Vaximm AG Major Business
    Table 127. Vaximm AG Neoantigen Vaccine Product and Services
    Table 128. Vaximm AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 129. Vaximm AG Recent Developments/Updates
    Table 130. Vaximm AG Competitive Strengths & Weaknesses
    Table 131. Medigene AG Basic Information, Area Served and Competitors
    Table 132. Medigene AG Major Business
    Table 133. Medigene AG Neoantigen Vaccine Product and Services
    Table 134. Medigene AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 135. Medigene AG Recent Developments/Updates
    Table 136. Medigene AG Competitive Strengths & Weaknesses
    Table 137. Genocea Biosciences Inc Basic Information, Area Served and Competitors
    Table 138. Genocea Biosciences Inc Major Business
    Table 139. Genocea Biosciences Inc Neoantigen Vaccine Product and Services
    Table 140. Genocea Biosciences Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 141. Genocea Biosciences Inc Recent Developments/Updates
    Table 142. Genocea Biosciences Inc Competitive Strengths & Weaknesses
    Table 143. Advaxis Basic Information, Area Served and Competitors
    Table 144. Advaxis Major Business
    Table 145. Advaxis Neoantigen Vaccine Product and Services
    Table 146. Advaxis Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 147. Advaxis Recent Developments/Updates
    Table 148. Nouscom Basic Information, Area Served and Competitors
    Table 149. Nouscom Major Business
    Table 150. Nouscom Neoantigen Vaccine Product and Services
    Table 151. Nouscom Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 152. Global Key Players of Neoantigen Vaccine Upstream (Raw Materials)
    Table 153. Neoantigen Vaccine Typical Customers
List of Figure
    Figure 1. Neoantigen Vaccine Picture
    Figure 2. World Neoantigen Vaccine Total Market Size: 2019 & 2023 & 2030, (USD Million)
    Figure 3. World Neoantigen Vaccine Total Market Size (2019-2030) & (USD Million)
    Figure 4. World Neoantigen Vaccine Revenue Market Share by Region (2019, 2023 and 2030) & (USD Million) , (by Headquarter Location)
    Figure 5. World Neoantigen Vaccine Revenue Market Share by Region (2019-2030), (by Headquarter Location)
    Figure 6. United States Based Company Neoantigen Vaccine Revenue (2019-2030) & (USD Million)
    Figure 7. China Based Company Neoantigen Vaccine Revenue (2019-2030) & (USD Million)
    Figure 8. Europe Based Company Neoantigen Vaccine Revenue (2019-2030) & (USD Million)
    Figure 9. Japan Based Company Neoantigen Vaccine Revenue (2019-2030) & (USD Million)
    Figure 10. South Korea Based Company Neoantigen Vaccine Revenue (2019-2030) & (USD Million)
    Figure 11. ASEAN Based Company Neoantigen Vaccine Revenue (2019-2030) & (USD Million)
    Figure 12. India Based Company Neoantigen Vaccine Revenue (2019-2030) & (USD Million)
    Figure 13. Neoantigen Vaccine Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Neoantigen Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 16. World Neoantigen Vaccine Consumption Value Market Share by Region (2019-2030)
    Figure 17. United States Neoantigen Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 18. China Neoantigen Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 19. Europe Neoantigen Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 20. Japan Neoantigen Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 21. South Korea Neoantigen Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 22. ASEAN Neoantigen Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 23. India Neoantigen Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 24. Producer Shipments of Neoantigen Vaccine by Player Revenue ($MM) and Market Share (%): 2023
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Neoantigen Vaccine Markets in 2023
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Neoantigen Vaccine Markets in 2023
    Figure 27. United States VS China: Neoantigen Vaccine Revenue Market Share Comparison (2019 & 2023 & 2030)
    Figure 28. United States VS China: Neoantigen Vaccine Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    Figure 29. World Neoantigen Vaccine Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Figure 30. World Neoantigen Vaccine Market Size Market Share by Type in 2023
    Figure 31. Personalized Vaccine
    Figure 32. Off-the shelf Vaccine
    Figure 33. World Neoantigen Vaccine Market Size Market Share by Type (2019-2030)
    Figure 34. World Neoantigen Vaccine Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Figure 35. World Neoantigen Vaccine Market Size Market Share by Application in 2023
    Figure 36. Lung Cancer
    Figure 37. Melanoma Cancer
    Figure 38. Gastrointestinal Cancer
    Figure 39. Brain Cancer
    Figure 40. Others
    Figure 41. Neoantigen Vaccine Industrial Chain
    Figure 42. Methodology
    Figure 43. Research Process and Data Source

Companies Mentioned

Pfizer
Merck & Co Inc
Eli Lilly and Company
BioNTech
Roche Holding AG
OSE Immunotherapeutics
Gritstone Bio
Moderna
Avidea Technologies
Vaccibody AS
Agenus Inc
Novogene
ZIOPHARM Oncology
ISA Pharmaceuticals
BrightPath Biotherapeutics
Vaximm AG
Medigene AG
Genocea Biosciences Inc
Advaxis
Nouscom